Metformin Blocks Chromatin Escape from the Nucleus to Curb Aging Inflammation

Chronic, low-grade inflammation—often called 'inflammaging'—is a hallmark of aging and underlies many age-associated diseases. Cytoplasmic chromatin fragments (CCFs), pieces of nuclear DNA that accumulate in the cytoplasm of senescent and aged cells, are potent activators of the cGAS–STING innate immune pathway and a major driver of this inflammation. However, because CCFs are physically larger than nuclear pores, the mechanism by which they transit from the nucleus to the cytoplasm has remained a fundamental open question.

This study, published in Nature Aging, demonstrates that CCFs exit the nucleus through nuclear egress—a vesicle-mediated membrane trafficking pathway previously known for shuttling large ribonucleoprotein complexes (such as herpesvirus capsids and megaRNPs) across the nuclear envelope. The researchers show that two critical nuclear egress complexes, ESCRT-III and the Torsin AAA-ATPase complex, are required for CCF translocation. Genetic inactivation of key components of these complexes caused chromatin fragments to accumulate at the inner nuclear membrane rather than reaching the cytoplasm, effectively trapping them and preventing cGAS–STING activation. This suppressed the senescence-associated secretory phenotype (SASP) and downstream inflammatory gene expression in senescent cells.

A central mechanistic finding connects cellular metabolism to this inflammatory pathway. Under glucose-limited conditions, or upon treatment with metformin (a widely used diabetes drug and candidate anti-aging compound), AMPK is activated. AMPK phosphorylates ALIX, a scaffolding component of the ESCRT-III machinery, marking it for autophagic degradation. Loss of ALIX disrupts the nuclear egress machinery, reducing CCF formation and cytoplasmic chromatin accumulation. This represents a direct molecular link between nutrient sensing, metabolic state, and the production of pro-inflammatory chromatin signals.

In vivo validation was provided using aged mice treated with metformin. In intestinal tissue—a tissue with high cell turnover and known susceptibility to age-related inflammation—metformin treatment reduced ALIX protein levels, decreased CCF abundance, and suppressed cGAS-mediated inflammatory signaling. These findings suggest that at least part of metformin's known anti-inflammatory and potential anti-aging effects may be mediated through this AMPK–ALIX–nuclear egress axis.

The study opens a new conceptual framework: nuclear egress, previously studied mainly in the context of viral biology and neuronal RNA export, is now implicated as a physiologically important pathway in mammalian aging and senescence-driven inflammation. Targeting this pathway—either through metabolic interventions like metformin or through direct inhibition of ESCRT-III or Torsin components—may represent a novel strategy to suppress inflammaging and age-associated pathology. Caveats include the reliance on mouse intestinal tissue for in vivo data, leaving open questions about other tissues and human relevance, and the need for further work to fully characterize the structural biology of chromatin fragment egress.